SEngine Precision Medicine closes Series A bringing total

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) — Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was … Read more